FIELD: chemistry.
SUBSTANCE: group of inventions relates to a mutant channel rhodopsins and to their respective applications. Light-activated ion channel contains an amino acid sequence which is at least 70 % homologus to amino acid sequence positions 1-309 SEQ ID NO: 1 (CHOP-2) and which contains a substitute in position corresponding to L132 in SEQ ID NO: 1.
EFFECT: higher channel polarity and conductivity of calcium increases at least twice as compared to wild type CHOP-2, as specified Fura-2 rendering on HEK293 cells.
16 cl, 7 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITING GENE EXPRESSION IN INSECT PESTS | 2018 |
|
RU2725953C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN-2 AND METHODS OF USE THEREOF | 2019 |
|
RU2826454C2 |
| SARS-CoV-2 ANTIBODIES AND METHODS OF USE THEREOF | 2021 |
|
RU2832025C1 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
